The therapeutic monoclonal antibody market.

Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.

The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 1.

The Fifth Annual Immunotherapeutics and Vaccine Summit (ImVacS), held in Boston, included topics covering new developments in the field of adjuvants and delivery systems for vaccines. This conference report highlights selected presentations on improving vaccine quality and persistence through adjuvants, the development of AS04-adjuvanted Cervarix, and research on new adjuvants. Adjuvants discussed include thymalfasin, nutritive immune-enhancing delivery system (NIDS), W805EC, MIMOPATH and ISCOMATRIX; the use of lasers as adjuvants is also highlighted.